Welcome to our dedicated page for Exponent SEC filings (Ticker: EXPO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The EXPO SEC filings page on Stock Titan provides access to Exponent, Inc.’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a Nasdaq-listed science and engineering consulting firm, Exponent uses SEC reports to present detailed information about its financial condition, operating performance, and material events. These filings complement the company’s earnings releases and offer structured data on revenues before reimbursements, operating expenses, segment performance, and non-GAAP measures such as EBITDA and EBITDAS.
Investors can use this page to locate Exponent’s periodic reports, including annual and quarterly filings that discuss its two operating segments: the engineering and other scientific segment and the environmental and health segment. These documents describe how much each segment contributes to revenues before reimbursements and provide narrative explanations of demand trends in areas such as dispute-related services, risk management projects, and regulatory consulting across industries like construction, automotive, medical devices, utilities, chemicals, transportation, and life sciences.
The EXPO filings page also highlights current reports on Form 8-K, where Exponent discloses material events. Recent 8-K filings have incorporated press releases announcing quarterly financial results, dividend declarations, and changes to share repurchase authorizations. These filings give timely insight into board decisions on capital returns and into management’s assessment of market conditions and business performance.
Stock Titan enhances access to these documents with AI-powered summaries that explain key sections in plain language, helping readers interpret complex accounting and technical terminology. Users can quickly see how Exponent’s reported metrics, segment data, and capital allocation actions fit into its broader consulting business. This makes the EXPO SEC filings page a useful starting point for understanding Exponent’s regulatory history and ongoing reporting as a professional, scientific, and technical services company.
Kundert Brian reported acquisition or exercise transactions in this Form 4 filing.
Exponent Inc. reported that Chief Human Resources Officer Brian Kundert received a grant of 3,564 restricted stock units on March 13, 2026. These units represent a 1-for-1 right to receive shares of common stock, typically as part of long-term equity compensation.
Following this award, he is reported as holding 3,564 restricted stock units directly. The transaction is recorded as a grant or award, not an open-market purchase or sale, and therefore reflects standard executive compensation rather than a discretionary trade.
Exponent Inc reported that Group Vice President James Bradley A received a grant of 4,454 Restricted Stock Units (RSUs) on March 13, 2026. These RSUs represent rights to receive an equal number of shares of common stock on a 1-for-1 basis.
The grant is a compensation-related award at no purchase cost, rather than an open-market transaction. Following this award, Bradley holds 4,454 RSUs directly. The RSUs are scheduled with an exercise and expiration date of March 13, 2030, indicating the expected settlement period for the underlying common shares.
Exponent Inc. President and CEO Catherine Corrigan received a grant of 17,814 restricted stock units on March 13, 2026. These RSUs are a form of equity compensation and are directly owned. Each unit is exchangeable on a 1-for-1 basis into Exponent common stock. Following this award, Corrigan holds 17,814 RSUs tied to an equivalent number of underlying common shares, with a stated conversion and expiration date of March 13, 2030.
Exponent Inc Group Vice President Richard Reiss reported routine equity compensation activity. He exercised 2,120 Restricted Stock Units granted on March 11, 2022, converting them into an equal number of common shares on a 1:1 basis. To cover related tax obligations, the company withheld 958 common shares at a value of $70.03 per share. After these transactions, Reiss directly holds 3,960 shares of Exponent common stock, indicating a net increase in his ownership from this award vesting and tax withholding event.
Exponent Inc.’s EVP & Chief Financial Officer Richard L. Schlenker Jr. exercised vested equity awards and had shares withheld for taxes. He converted 7,630 Restricted Stock Units granted on March 11, 2022 into 7,630 shares of Common Stock on a 1:1 basis. To satisfy tax withholding obligations, 3,694 Common Stock shares were withheld by the company, leaving him with 230,351 Common Stock shares held directly after these transactions. These actions represent routine equity compensation vesting and related tax settlement rather than open-market buying or selling.
EXPONENT INC Group Vice President Joseph Sala reported compensation-related equity activity. On March 11, 2026, he exercised 3,180 Restricted Stock Units granted on March 11, 2022, converting them into 3,180 shares of Common Stock on a 1:1 basis.
To cover tax withholding obligations, 1,114 of these shares were withheld by the company at a value of $70.03 per share, leaving Sala with 2,066 shares of Common Stock held directly after the transactions. The filing shows no remaining derivative (RSU) position from this grant.
Exponent Inc. Group Vice President Maureen T. F. Reitman exercised restricted stock units and settled related taxes in shares. On March 11, 2026, 5,510 vested Restricted Stock Units granted on March 11, 2022 were converted into 5,510 shares of Common Stock on a 1:1 basis.
To satisfy tax withholding obligations, 1,756 shares of Common Stock were withheld by the company at $70.03 per share. After these transactions, Reitman directly owned 39,226 shares of Exponent Common Stock, reflecting a routine compensation-related vesting and tax withholding event rather than an open-market sale.
Exponent Inc. Group Vice President Joseph Rakow exercised vested equity awards and received new common shares. He converted 5,298 Restricted Stock Units, granted on March 11, 2022, into 5,298 shares of Common Stock on a 1:1 basis. To cover tax withholding obligations, the company withheld 2,353 shares at a value of $70.03 per share, leaving Rakow with 2,945 shares of Common Stock held directly after the transactions. These movements reflect routine equity compensation vesting and associated tax withholding, rather than open-market buying or selling.
Exponent Inc. executive John Pye reported routine equity compensation activity involving restricted stock units and common shares. On March 11, 2026, 5,934 vested restricted stock units were converted into 5,934 shares of common stock on a 1:1 basis, reflecting the vesting of awards originally granted on March 11, 2022.
To cover tax withholding obligations tied to this vesting, 2,384 common shares were withheld by the company at a price of $70.03 per share, a tax-related disposition rather than an open-market sale. After these transactions, Pye directly holds 29,131 shares of Exponent common stock.
Exponent Inc. Group Vice President James Bradley reported routine equity compensation activity. On March 11, 2026, 4,664 vested Restricted Stock Units granted on March 11, 2022 converted into 4,664 shares of common stock on a 1:1 basis. To satisfy tax withholding obligations, the company withheld 1,559 of these shares at a price of $70.03 per share. Bradley retained 3,105 common shares directly following the transactions. The withholding is a tax payment mechanism, not an open-market sale.